RESOURCES > Federal Register Notices > Rules - 2021
Rules - 2021
DEA Form 222
Direct Final Rule: Clarification Regarding the Supplier's DEA Registration Number on the Single-Sheet DEA Form 222 (July 20, 2021)
Drug Scheduling Actions
Final Order: Placement of Isotonitazene in Schedule I (PDF) (November 4, 2021)
Final Rule: Placement of 4,4'-DMAR in Schedule I (August 12, 2021)
Final Rule: Registration Requirements for Narcotic Treatment Programs With Mobile Components (PDF) (June 28, 2021)
Final Rule: Placement of para-Methoxymethamphetamine (PMMA) in Schedule I (June 25, 2021)
Final Rule: Specific Listing for 4F-MDMB-BINACA, a Currently Controlled Schedule I Substance (June 22, 2021)
Final Rule: Placement of N-Ethylpentylone in Schedule I (June 14, 2021)
Final Rule: Placement of Oliceridine in Schedule II (June 10, 2021)
Final Rule: Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA, and 5F-CUMYL-P7AICA in Schedule I (June 10, 2021)
Final Rule: Placement of Remimazolam in Schedule IV (June 2, 2021)
Final Rule: Placement of Lasmiditan in Schedule V (May 24, 2021)
Interim Final Rule: Placement of Serdexmethylphenidate in Schedule IV (May 7, 2021)
Final Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (May 4, 2021)
Final Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (April 27, 2021)
Final Rule: Removal of Samidorphan From Control (April 19, 2021)
Extension of Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I of the Controlled Substances Act (March 31, 2021)
Final Rule: Placement of Lemborexant in Schedule IV (March 3, 2021)
Temporary Placement of Brorphine in Schedule I (March 1, 2021)
Exempt Chemical Preparations Under the Controlled Substances Act
Order with Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (July 22, 2021)
Exempt Chemical Preparations Under the Controlled Substances Act (PDF) (April 23, 2021)
Proposed Rules
Proposed Rule: Placement of Methoxetamine (MXE) in Schedule I (PDF) (December 7, 2021)
Proposed Rule: Transfer of Electronic Prescriptions for Schedules II-V Controlled Substances between Pharmacies for Initial Filling (PDF) (November 19, 2021)
Proposed Rule: Regulation of Telepharmacy Practice (PDF) (November 17, 2021)
Proposed Rule: Removal of [\18\F]FP-CIT From Control (PDF) (November 4, 2021)
Proposed Rule: Placement of Methiopropamine in Schedule I (September 2, 2021)
Proposed Rule: Placement of Mesocarb in Schedule I (August 11, 2021)
Proposed Rule: Placement of Amineptine in Schedule I (July 22, 2021)
Proposed Rule: Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA and FUB-144 in Schedule I (March 30, 2021)
Proposed Rule: Placement of Four Specific Fentanyl-Related Substances in Schedule I (March 18, 2021)
Proposed Rule: Placement of 10 Specific Fentanyl-Related Substances in Schedule I (March 3, 2021)
Proposed Rule; Reopening of Comment Period: Suspicious Orders of Controlled Substances (February 25, 2021)
Proposed Rule: Amending Regulations To Require Online Submission of Applications for and Renewals of DEA Registration (PDF) (January 7, 2021)
Registration
Final Rule: Addition of the United States Space Force as a Registration Waiver and Registration Fee Exempt Military Entity (September 17, 2021)
NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).